Article
02 Jul 2024
The USPTO Proposes A Radical Change To Terminal Disclaimer Practice: You Have An Opportunity To Comment
AUTHORS CONTENT
Article
24 May 2024
The Appeals Review Panel's In Re Xencor Decision: The USPTO Provides Its Position On Written Description And Means-Plus-Function Claims
Article
15 Apr 2024
Janssen v. Teva: Not An April Fool's Day Joke For Life Sciences Companies
Article
03 Apr 2024
USPTO Emphasizes Searches Of FDA Databases For Pharmaceutical Patent Applications
Article
19 Mar 2024
USPTO's New Guidance On AI-Assisted Inventions: The Impact On The Use Of AI In The Life Sciences
Article
12 Feb 2024
Life Sciences Companies Make Up A Small Portion Of The Companies Opting-In To The Unitary Patent; Ireland Announces Referendum Date
Article
06 Feb 2024
USPTO Publishes Enablement Guidelines In View Of Amgen v. Sanofi
Article
05 Feb 2024
Federal Circuit Remands To USPTO To Clarify Analysis Of Jepson-Format And Means-Plus-Function Claims In The Field Of Biotechnology
Article
31 Jan 2024
K-Fee Provides A Warning To Life Sciences Companies – What You Say In Foreign Prosecution May Affect Your U.S. Claim Scope
Article
11 Jan 2024
District Court Grants Summary Judgment And Invalidates Patent In REGENXBIO v. Sarepta Litigation
Article
22 Dec 2023
Federal Government Releases Proposed Guidance For Exercising "March-In" Rights Under The Bayh-Dole Act: Q & A
Article
19 Dec 2023
Federal Government Releases Proposed Guidance For Exercising "March-In" Rights Under The Bayh-Dole Act: Implications For Pharmaceutical And Medical Technology Companies
Article
23 Oct 2023
Some Much-Needed (Applicant-Friendly) Clarification On Priority Claims At The European Patent Office
Article
23 May 2023
Proposed USPTO Fee Changes Could Impact PGR And IPR Filing Strategies Used By Biosimilars
Article
17 May 2023
Proposed USPTO Fee Changes Will Make It Much More Expensive To Patent And To Challenge Patents On Therapeutics. You Have An Opportunity To Comment...
Article
23 Jan 2023
USPTO Launches The Cancer Moonshot Expedited Examination Pilot Program
Article
21 Dec 2022
Decision Time: The Unified Patent Court Begins In 2023
Article
26 Sep 2022
Executive Order For Advancing Biotechnology And Biomanufacturing Innovation Signed By President Biden
Article
20 Sep 2022
European Regulatory Heads Make Biosimilars Interchangeable
Article
19 Aug 2022
The USPTO's Increasing Focus On FDA Submissions And The Duty Of Disclosure